Incyte (INCY) is trading higher today as investors react to the company’s Q1 2026 earnings release and business update posted on April 28, 2026. The report showed total revenue of $1.27 billion and total net sales of $1.10 billion, representing year-over-year increases of 21% and 20%, respectively, and management reiterated full-year 2026 net sales guidance of $4.77–$4.94 billion. (biospace.com)

The company attributed the sales lift primarily to demand for Jakafi across indications, continued momentum for Opzelura (atopic dermatitis and vitiligo), and growth in newer and partnered/adjacent oncology/hematology products including Niktimvo, Monjuvi and Zynyz. Within the release, Incyte detailed Jakafi net sales of $758 million (+7% year over year) and Opzelura net sales of $143 million (+20% year over year), alongside a sharp increase in hematology/oncology net sales to $204 million (+116% year over year). (biospace.com)

Beyond the quarter’s commercial execution, traders focused on a fresh late-stage pipeline catalyst: Incyte disclosed positive Phase 3 results for povorcitinib in nonsegmental vitiligo, with both Phase 3 studies (STOP-V1 and STOP-V2) meeting the primary endpoint at Week 52. Incyte said the data are expected to support regulatory applications for vitiligo planned for the first half of 2027, adding another potential growth lever beyond its established JAK franchise. (biospace.com)

The next near-term focus is whether Incyte can sustain Jakafi durability while scaling Opzelura and building meaningful contribution from its expanding late-stage portfolio. Investors will also track upcoming 2026 milestones flagged by the company, including additional clinical data releases in the second half of 2026 and anticipated regulatory decision timing for Jakafi XR in mid-2026. (biospace.com)